Assessment of costs associated with adverse events in patients with cancer-Reference-Cited by-同舟云学术

Assessment of costs associated with adverse events in patients with cancer

Published:2018-04-13 Issue:4 Volume:13 Page:e0196007
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wong William,Yim Yeun Mi,Kim Ashley,Cloutier Martin^ORCID,Gauthier-Loiselle Marjolaine,Gagnon-Sanschagrin Patrick,Guerin Annie

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options;LE Schnipper;J Clin Oncol,2015

2. New Frameworks to Assess Value of Cancer Care: Strengths and Limitations;LE Schnipper;Oncologist,2016

3. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice;D Weycker;BMC Cancer,2012

4. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer;CT Pike;Chemother Res Pract,2012

5. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States;D Latremouille-Viau;J Med Econ,2017

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing nurse competence in early recognition of cardiotoxicity;Cardio-Oncology;2024-09-14

2. Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective;Journal of Medical Economics;2024-09-10

3. Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cancer;Journal of Managed Care & Specialty Pharmacy;2024-09

4. Is bevacizumab a cost‑effective regimen for treating cerebral radiation necrosis in the United States?;Practical Radiation Oncology;2024-08

5. Datopotamab deruxtecan versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer: A cost-effectiveness analysis;Lung Cancer;2024-08